Cidara Therapeutics (CDTX) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for July 18, 2024, to be held virtually, with voting on key proposals including director elections, amendments to the certificate of incorporation, equity incentive plans, and auditor ratification.

• Stockholders of record as of May 28, 2024, are eligible to vote on seven proposals, with detailed instructions provided for voting by internet, phone, or mail.

• The company is seeking approval for significant changes to its capital structure and executive compensation plans, reflecting recent strategic transactions and capital raises.

Voting matters and shareholder proposals

• Election of three Class III directors to serve until the 2027 annual meeting.

• Amendment to increase authorized common stock from 20,000,000 to 50,000,000 shares.

• Approval of potential change of control from conversion of Series A Preferred Stock.

• Approval of the 2024 Equity Incentive Plan, replacing the 2015 plan.

• Ratification of Ernst & Young LLP as independent auditor for 2024.

• Advisory vote on executive compensation (say-on-pay).

• Approval to adjourn the meeting if more votes are needed for key proposals.

Board of directors and corporate governance

• The board consists of nine members, with a majority deemed independent under Nasdaq rules.

• Board leadership is separated between the Chairman and CEO roles to reinforce independence.

• Committees include Audit, Compensation and Human Capital, and Nominating and Governance, with all committee members meeting independence requirements.

• Board diversity is highlighted, with 38% female directors and a focus on inclusion.